Latest ROE for Pliant Therapeutics: -62.81% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-62.81%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Pliant Therapeutics (PLRX) currently reports a ROE of -62.81%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Pliant Therapeutics's ROE history and peer comparisons.
Pliant Therapeutics's ROE of -62.81% is lower than the Healthcare sector average of 11.15%. That is roughly 663.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Pliant Therapeutics's current -62.81% should be judged against Healthcare norms (sector average: 11.15%) and against PLRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -62.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Pliant Therapeutics, and consider following PLRX for alerts when major investors trade the stock.
Pliant Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -62.81% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLRX with unrelated industries.